Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

"Bright spotty lesions" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis.
Optic Neuritis Probably Induced by Isotretinoin.
New technologies for biomarker discovery in multiple sclerosis.
Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
Multiple sclerosis.
Modeling the heterogeneity of multiple sclerosis in animals.
Association between pathological and MRI findings in multiple sclerosis.
[Lyme disease in patients with multiple sclerosis: clinical, diagnostic and therapeutic features.]
Clinical analysis of the etiology of optic neuritis in patients at different ages in china.
Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States.
Magnetic Resonance Spectroscopy to Assess NeuroInflammation and Neuropathic Pain.
The gut microbiota and its correlations with the central nervous system disorders.
MR imaging findings of the corpus callosum region in the differentiation between multiple sclerosis and neuromyelitis optica.
Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation.
Effects of phenytoin on the persistent Na+ current of mammalian CNS neurones.
Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes.
FTY720 mediates activation suppression and G(0)/G (1) cell cycle arrest in a concanavalin A-induced mouse lymphocyte pan-activation model.
Polyunsaturated fatty acids in multiple sclerosis therapy.
Role of Proangiogenic Factors in Immunopathogenesis of Multiple Sclerosis.
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Cortical Perfusion Alteration in Normal-Appearing Gray Matter Is Most Sensitive to Disease Progression in Relapsing-Remitting Multiple Sclerosis.
Disclosing the diagnosis of multiple sclerosis: The Profile Project.
Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS
Fingolimod (FTY720) stimulates ca(2+)/calcineurin signaling in fission yeast.
Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ

Pages